Biological base recognized in innovation ranking

The Shenzhen State Biological Industry Base in Pingshan District was ranked fourth on the 2025 list of the Most Innovative Bio-Manufacturing National Bioindustry Bases, which was recently released at the 17th China Bioindustry Convention.

A view of the Shenzhen Biomedicine Innovations Industrial Park within the Shenzhen State Biological Industry Base in Pingshan District. Shenzhen Economic Daily

Approved by the National Development and Reform Commission in June 2005 as one of the first three national bioindustry bases, the Shenzhen State Biological Industry Base covers 3.29 square kilometers of planned area. Focusing on biopharmaceuticals, medical devices, and bio-services, it is regarded as one of China’s most market-oriented and well-equipped bases for high-tech development and commercialization.

As Shenzhen’s core biopharmaceutical cluster and a catalyst for high-end medical device manufacturing, Pingshan is building a full-chain service system covering R&D, commercialization, and production. The district hosts 16 industrial parks in this sector, including the Shenzhen Biomedicine Innovations Industrial Park and the Biomedical Enterprise Accelerator Phase 2, which together provide more than 2.5 million square meters of high-quality industrial space.

Pingshan has introduced targeted policies to support the development of biopharmaceuticals and innovative drugs, offering strong support for R&D, industrialization, and internationalization. The Shenzhen Biopharmaceutical Industry Fund has grown into a 5-billion-yuan fund cluster that provides targeted financial support to innovators.

The district has also launched a rapid drug and medical device approval service mechanism that links municipal, district, and park levels. Key platforms for drug and device development and registration have been established to provide one-stop support for faster approvals and market entry.